Abstract 31: Targeted dissociation of PF1 from SIN3A chromatin regulator complex inhibits tumor growth and metastasis in triple-negative breast cancer
Authors: Kadamb Rama , Bansal Nidhi , Leibovitch Boris A , Kwon Yeon-Jin , Zhou Ming-Ming , Farias Eduardo , Waxman Samuel 
Published: August 2018

Triple negative breast cancer (TNBC) is characterized by an aggressive, poorly differentiated phenotype associated with early recurrence. Chemotherapy is the only treatment option due to the lack of an effective molecular target. Targeting reversible epigenetic alterations in TNBC to reprogram the TNBC phenotype may increase chemosensitivity and identify effective targeted therapies. The SIN3 chromatin modifier complex is a multidomain scaffold protein which plays a key role in multiple cellular functions including epigenetic gene expression regulation, making SIN3 a potential therapeutic target. The PAH-2 domain of SIN3 binds with different affinities to a group of proteins that contain variations of an amino acid sequence known as the SIN3 interaction domain (SID). We previously reported the effects of blocking PAH-2 interaction with MAD-1, a SID sequence containing protein by using SID peptides and small molecule inhibitors (SMI) as decoys. We now report the effects of blocking the PAH-2 binding of PF1 and TGIF1, two other Sin3 interacting proteins with different amino acid sequence and PAH-2 binding affinities. Treatment with MAD-1 SID peptide and SMI revert the epithelial to mesenchymal transition (EMT) process, inhibit cancer stem cells expansion, cell invasion, tumor growth and metastasis development in human and mouse models of TNBC. TGIF1 interaction with SIN3 is associated with the invasive phenotype and EMT regulation by modulating wnt signaling and inhibiting beta catenin nuclear localization which is reverted by TGIF1 knockdown. PF1, which binds MRG15 and KDM5A/B, an epigenetic modifier, is involved in the regulation of cancer stem cell compartment expansion, DNA damage control, senescence, apoptosis and the expression of genes involved in metastatic progression. Interestingly, decrease in H3K4me3 is found in stem cell and EMT genes following 72 hour SID peptide treatment. PF1 dissociation from Sin3 by transfecting MDA-MB-231 and 4T1 cells with a PF1-SID expressing vector grown in 3D morphogenesis cultures display the formation of small organoids in the MDA-MB-231PF1-SID and tubular morphogenesis in the 4T1PF1-SID cells. There is increased activated caspase-3 and γH2AX, reduced Ki67, tenascin-C and marked cortical actin reorganization. This is accompanied by small organized colonies with loss of invasive and proliferative phenotype. In vivo, 4T1PF1-SID barely form tumors and have a 95% decrease in lung metastasis. These results show that decoys can be designed to block specific proteins that bind to the PAH-2 domain resulting in different outcomes which contribute to a common effect on inhibition of tumor progression and metastasis dissemination. Therefore, this strategy opens a potential therapeutic alternative for TNBC patients for whom there are no other therapeutic options besides chemotherapy.

Citation Format: Rama Kadamb, Nidhi Bansal, Boris A Leibovitch, Yeon-Jin Kwon, Ming-Ming Zhou, Eduardo Farias, Samuel Waxman. Targeted dissociation of PF1 from SIN3A chromatin regulator complex inhibits tumor growth and metastasis in triple-negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 31.